ANVS

Annovis Bio, Inc.

1.38 USD

Last updated Sep 5, 11:47 UTC

Yesterday HIGH

$1.44

Yesterday LOW

$1.38

52w HIGH

$5.5

52w LOW

$1.32

EPS

-0.40

PE

-3.45

Next Earnings

Nov 11, 2026

Overview News Government Trades Fundamentals

Annovis Bio, Inc. stock is down -25.81% since 30 days ago. The next earnings date is Nov 11, 2026. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 23 September’s closed higher than August. 100% of analysts rate it a buy.

Benzinga Newsdesk

Tue May 19, 2026

Annovis Bio Announces Launch Of Proposed $250M Public Stock Offering Initially Filed February 12, 2024
Benzinga Newsdesk

Fri May 15, 2026

Annovis Bio Q1 EPS $(0.63) Misses $(0.40) Estimate

Annovis Bio (NYSE:ANVS) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.40) by 61.54 percent. This is a 96.88 percent decrease over losses of $(0.32) per share from the
Benzinga Newsdesk

Tue Apr 28, 2026

Annovis Bio Announces New Publication Titled Buntanetap Treatment In Mild To Moderate Alzheimer's Disease: Phase 2/3 Study In Peer-Reviewed Journal Nature NPJ Dementia

Buntanetap improved cognition in pTau217-positive early AD patientsThe drug reduced neurotoxic proteins as well as biomarkers of neuroinflammation and neurodegenerationBuntanetap was safe and well-tolerated, including in
Benzinga Newsdesk

Fri Apr 10, 2026

Annovis Bio Closes Underwritten Public Offering Raising ~$10M In Gross Proceeds; Financing Secures Path To First NDA Submission For Buntanetap

Financing secures path to first NDA submission for buntanetap6-Month symptomatic data readout anticipated Q1 2027Alzheimer's disease Phase 3 trial 75% enrolledParkinson's disease open-label study 28% enrolledMALVERN,
Benzinga Insights

Thu Apr 9, 2026

12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Newsdesk

Thu Apr 9, 2026

Annovis Bio shares are trading lower after the company announced pricing of its $10 million offering of common stock and warrants.
Benzinga Newsdesk

Thu Apr 9, 2026

Annovis Bio Prices Underwritten Offering Of 5.3m Shares And Warrants At $1.90 Per Unit
Benzinga Newsdesk

Mon Apr 6, 2026

Annovis Bio shares are trading higher after a Form 4 filing showed that a Director purchased 713,800 shares at $2.10 per share.
Benzinga Insights

Mon Apr 6, 2026

12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Newsdesk

Thu Apr 2, 2026

Annovis Bio Issued New U.S. Patent For Prevention And Treatment Of Neurological Injuries From Brain Infections

Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's

Roth Capital

Fri Aug 28, 19:16

buy

confirm
Canaccord Genuity

Tue Aug 18, 17:06

buy

confirm

Advanced Data Unlock

BRUN BRUN $17.34 USD

CRCL $101.56 USD

HROW $38.54 USD

AXSM $206.56 USD

VKTX $34.86 USD

FSLR $204.53 USD

IBIT IBIT $45.24 USD

MDB $368.34 USD